Singapore markets close in 2 hours 45 minutes

  • Straits Times Index

    3,184.57
    -3.21 (-0.10%)
     

  • Nikkei

    29,004.99
    -183.18 (-0.63%)
     

  • Hang Seng

    28,952.66
    +197.32 (+0.69%)
     

  • FTSE 100

    6,938.24
    +42.95 (+0.62%)
     

  • BTC-USD

    49,340.33
    -4,932.75 (-9.09%)
     

  • CMC Crypto 200

    1,119.96
    -123.09 (-9.90%)
     

  • S&P 500

    4,134.98
    -38.44 (-0.92%)
     

  • Dow

    33,815.90
    -321.41 (-0.94%)
     

  • Nasdaq

    13,818.41
    -131.81 (-0.94%)
     

  • Gold

    1,786.30
    +4.30 (+0.24%)
     

  • Crude Oil

    61.85
    +0.42 (+0.68%)
     

  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,608.23
    +0.50 (+0.03%)
     

  • Jakarta Composite Index

    6,008.41
    +14.23 (+0.24%)
     

  • PSE Index

    6,378.07
    -37.46 (-0.58%)
     

Best schools in Singapore to get an MBA

Elena Torrijos

What schools should you consider if you want to get a good master's degree in business administration in Singapore?

According to the Financial Times' Global MBA Rankings 2012, there are four schools in the city-state on the top 100 list.

Graduate school INSEAD's France and Singapore campuses jointly ranked the highest of the four at sixth place, down a couple of notches from its fourth-place ranking the previous year.

Graduates from the school today earn US$144,422 or 97 per cent more than what they used to earn before getting their MBA degrees, according to FT's data.

The National University of Singapore's School of Business retained its 23rd place on the list for the second time in a row, the highest ranking attained by a local institution.

The school did well in several categories. In a statement, NUS said salaries of graduates shot up 185 per cent over their salaries before getting the MBA. Today, the graduates earn about US$98,430.

It also kept its place ninth-place ranking in the world for its graduates' international mobility, reflecting the broad international demand from employers for the school's MBA graduates.

"For many of us, the programme opened our minds to new ideas, new horizons, and the ability to take up new challenges at work," said Michael Teng, president of MBA Alumni-NUS.

Nanyang Business School of Nanyang Technological University ranked 34th on the list, one notch down from the ranking the year before.

In a statement, the school said that its graduates enjoy the highest average salaries among Singapore MBA programs with an average pay of US$102,350 a year, three years after graduation.

It also noted that its MBA programme ranks first in Singapore for career progression opportunities and successful job placements offered to its graduates.

Tomoyuku Suzuki, 35, who graduated from the school in 2008, said the MBA degree has enabled him to successfully switch careers from business development to management consulting, enabling him to expand his responsibilities. His remuneration is 70 per cent higher now compared to the level before obtaining his MBA from the Singapore university.

The fourth school on the top 100 list is SP Jain Center of Management, which has campuses in Dubai and Singapore. FT's list showed graduates from the school earn close to US$79,000 or 146 per cent pre-MBA.

If staying in Singapore isn't an issue, then the top five schools for MBA programmes in the world according to FT are, in order:

Stanford Graduate School of Business
Harvard Business School
University of Pennsylvania: Wharton
London School of Business
Columbia Business School

The Financial Times Global MBA Ranking is based upon data from business schools and their alumni. Three main areas are analysed: alumni career progress, diversity of students and faculty, and ideas generation.

Rankings are heavily weighted on salary and salary increase three years after graduation. Both measures each account for 20 per cent of a school's rank, and are considerably sensitive to the countries the school's alumni were working in before and after the MBA programme.

Latest stories

  • Bilia acquires Upplands Motor Stockholm AB, a Mercedes dealer for cars, transport vehicles and trucks

    Bilia has today concluded an agreement to acquire an authorised Mercedes dealer, Upplands Motor Stockholm AB, who conduct sales and service operations for Mercedes cars, transport vehicles and trucks at four facilities in the Stockholm area in Sweden. The agreement is subject to approval by the Swedish competition authority. Bilia is expecting to take over the operations on 1 July 2021. The business that is acquired reported for 2020 a turnover of about SEK 1,200 M and an operating profit of SEK 48 M. The number of employees is about 250. The operation’s capital employed and agreed surplus values amount to about SEK 220 M. The Bilia Group’s capital employed and net debt are estimated to increase, related to the acquisition, by about SEK 350 M. Per Avander, Bilia’s MD and CEO, comments:”I’m very happy and proud that Bilia in the future will work with Mercedes, which will be an excellent addition to Bilia’s current car brand portfolio. Through the acquisition, we are also adding a new and interesting business area to Bilia in the form of heavy trucks, in which Mercedes is one of Europe’s largest and most successful players.” Oskar Lindström, Chairman of the Board at Upplands Motor Holding, comments:”We are very happy to have Bilia as new owner of Upplands Motor’s Mercedes operations. Bilia’s customer focus, competence and experience are important in the further development of the Mercedes business. A business that we are proud to have been entrusted with from Mercedes-Benz to develop in Stockholm. Bilia becomes a strong partner to Mercedes-Benz to continue that work.” Niels Kowollik, MD Mercedes Sweden, comments:”I’m pleased that Bilia, as one of Sweden’s most experienced and knowledgeable players, who also has experience of working with premium brands, has acquired Upplands Motor. They are good at offering concepts that are appreciated by customers, which we see as an important part of future car sales. I look forward to a good collaboration with Bilia.” Gothenburg, April 23, 2021 Bilia AB (publ) This is information that Bilia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on April 23, 2021, at 08:10 CEST. For information please contact: Per Avander, Managing Director and CEO, +46 (0)10 497 70 00, per.avander@bilia.se Kristina Franzén, CFO, +46 (0)10 497 73 40, kristina.franzen@bilia.se Facts about the Bilia Group Bilia is one of Europe’s largest car dealers with a leading position within service and sales of cars and transport vehicles. Bilia has about 140 facilities in Sweden, Norway, Germany, Luxembourg and Belgium. Bilia sells cars of the brand Volvo, BMW, Toyota, Renault, Lexus, MINI, Dacia, Alpine and transport vehicles of the brand Renault, Toyota and Dacia. Bilia offers new and used cars, e-commerce, spare parts and store sales, service and repair workshops, tyres and car glass and financing, insurance, car washes, fuel stations and car dismantling under the same roof, which gives a unique customer offer. Bilia reported a turnover of about SEK 30 Bn in 2020 and had about 4,700 employees. Attachment Bilia acquires Upplands Motor Stockholm AB, a Mercedes dealer for cars, transport vehicles and trucks

  • Slick Vision Tattoo & Laser Removal Brings Fast and Effective Laser Tattoo Removal to the Island of Oahu Featuring the Astanza Duality Laser

    Aiea, Hawaii, April 23, 2021 (GLOBE NEWSWIRE) -- Slick Vision Tattoo & Laser Removal is home to Aiea, Hawaii’s most talented tattoo artists. The up-and-coming tattoo and laser removal studio is a one-stop-shop for anyone looking to get a new tattoo, remove an unwanted tattoo, or modify an existing tattoo. Slick Vision Tattoo & Laser Removal specializes in removing tattoo regret with complete tattoo removal, tattoo lightening for cover-ups, and selective removal for partial modification. Slick Vision Tattoo & Laser Removal uses the Astanza Duality laser to perform all laser tattoo removal services and help residents in the island of Oahu achieve their skin’s desired look. “Slick Vision Tattoo & Laser Removal was founded in hopes of helping people feel happy and comfortable in their skin. As tattoo artists, we love seeing the power that tattoos have on an individual. However, we also know the negative impact an unwanted tattoo or old can have on a person,” said Jayson Ramoran, owner. “With laser tattoo removal, we can erase tattoos that people no longer identify with, fade tattoos to create better cover-ups, and remove a specific part of a tattoo, like a name, without touching the surrounding ink. We are excited to introduce the Astanza Duality to local residents and continue delivering the best artwork.” The Astanza Duality is a cutting-edge Q-switched Nd:YAG device that uses ultra-quick pulse durations and intense peak power to safely shatter unwanted ink in the skin. The Duality is revered as one of the best lasers on the market and is trusted by leading physicians, medical spas, tattoo artists, and laser technicians worldwide. The Duality’s 532 nm and 1064 nm wavelengths can target and remove a wide variety of tattoo colors and are safe to use on all skin types. “Jayson and the Slick Vision Tattoo & Laser Removal team are a group of passionate tattoo lovers,” said Opal Taskila, Astanza Sales Representative. “Their investment in the Duality is proof of their commitment to delivering the best tattoo and laser removal results throughout the island of Oahu.” About Slick Vision Tattoo & Laser Removal Slick Vision Tattoo & Laser Removal is a full-service tattoo studio and laser tattoo removal shop located in Aiea, Hawaii. They provide expert tattooing, complete tattoo removal, selective tattoo removal, and fading for cover-ups. Their laser technicians received expert training from New Look Laser College, the world’s leading laser tattoo removal training program, and received the designations of Certified Laser Specialist (CLS) and Laser Safety Officer (LSO). To schedule a consultation or learn more about their services, visit https://www.slickvisiontattooandlaserremoval.com/ and follow them on Instagram. Slick Vision Tattoo & Removal is located at the Aiea Commercial Center, 99-185 Moanalua Rd. Suite 103 Aiea, Hawaii 96701. About Astanza Laser Astanza is the leader in lasers for tattoo removal, hair removal, and additional aesthetic procedures. In addition to delivering cutting-edge medical laser devices such as the Duality, Trinity, MeDioStar, and DermaBlate systems, Astanza offers its customers a complete range of training, marketing, and business consulting services to achieve success in this growing field. Astanza is an award-winning company that has received several accolades from leading industry organizations, including MyFaceMyBody and Aesthetic Everything. They are also certified as a “Great Place to Work”. Astanza Laser is headquartered in Dallas, TX, with customers throughout North America and Europe. For product, investor, or press information, call (800) 364-9010, or visit https://astanzalaser.com/. Connect with Astanza on LinkedIn, Facebook, Instagram, Twitter, and YouTube. CONTACT: Astanza Laser Astanza Laser (800) 364-9010 info@astanzalaser.com

  • Bodycam footage shows police beating black man for littering

    ‘What I saw in the video was another George Floyd,’ attorney says

  • St George’s Day: Six reasons why England’s patron saint is a symbol of multiculturalism

    Thought George was just the patron saint of England? Think again

  • Dividend Payment Procedure

    Šiaulių Bankas AB, company code 112025254, domicile address Tilžės st. 149, LT-76348 Šiauliai, Lithuania.The General meeting of shareholders held on 31 March 2021 approved allocation of the profit of Šiaulių Bankas AB which included a pay-out of dividends - 0.0055 euro shall be paid for each ordinary registered share with a nominal value of 0.29 euro. Dividends shall be paid out to persons who were the shareholders of Šiaulių Bankas AB at the end of the record day - 15 April 2021. The Bank shall pay out dividends on 28 April 2021 in compliance with the following procedure:- those shareholders whose shares are being accounted in the securities accounts with banks and financial brokerage companies rendering investment services will receive an amount of dividends after deduction of Personal Income Tax or Corporate Profit Tax in compliance with the laws of the Republic of Lithuania which shall be transferred to the accounts with the respective banks or financial brokerage companies; - for shareholders whose shares are accounted for in Šiaulių Bankas AB in the issuer's accounting, the amount of dividends, after deducting personal income tax or income tax in accordance with the laws of the Republic of Lithuania, will be transferred to the account with Šiaulių Bankas AB specified by the shareholder. If the shareholder has not specified an account with Šiaulių Bankas AB for the transfer of dividends, he/she must submit an application for the transfer of dividends. Applications are accepted from 28 April 2021 in all customer service points of Šiaulių Bankas AB. As long as the quarantine regime is in force, in accordance with security requirements, before going to the customer service department, it is necessary to register for a visit on-line at www.sb.lt or by phone 1813. Applications for dividend transfer can also be submitted via the bank's online banking. Taxation of dividends:- Dividends of natural persons residents of the Republic of Lithuania and foreign countries shall be subject to 15 per cent of the Personal Income Tax rate; - Dividends of legal entities residents of the Republic of Lithuania and foreign countries shall be subject to 15 per cent of the Corporate Profit Tax rate, unless otherwise provided for in the laws. Additional information:Director of Securities Accounting Department Jolanta Dobiliauskienė+370 41 595 669, e-mail jolanta.dobiliauskiene@sb.lt

  • India’s Covid nightmare – photo essay

    India’s Covid nightmare – photo essay. As a new global record 314,835 for new Covid cases is set in India, hospitals are running out of oxygen and bodies are stacking up in morgues

  • From Line of Duty-core to fake houseplants: this week’s fashion trends

    From Line of Duty-core to fake houseplants: this week’s fashion trends. What’s hot and what’s not in fashion this week

  • Prince Charles’s model village architecture? Give me brutalism any day

    Prince Charles’s model village architecture? Give me brutalism any day. There is a large cohort of people who despise the look, but I am a broad church when it comes to architecture

  • House of Cardin review – genial fashion futurist with an eye for expansion

    House of Cardin review – genial fashion futurist with an eye for expansion. Aside from some breathless celebrity endorsements, Pierre Cardin comes across as a designer ahead of his time, explored in a respectful, decent doc

  • Opponents of LTNs claim they delay emergency services – but look at the facts

    Opponents of LTNs claim they delay emergency services – but look at the facts. One thing is clear: there is virtually no evidence that low-traffic neighbourhood schemes hold up emergency vehicles

  • This war graves report shows Britain must face its colonial past with honesty

    This war graves report shows Britain must face its colonial past with honesty. Hundreds of thousands of soldiers who died for Britain went unremembered, simply because of their race

  • Director/PDMR Shareholding

    Kenmare Resources plc (“Kenmare” or “the Group”) 23 April 2021 Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation) 1Details of the person discharging managerial responsibilities/person closely associateda)NameELAINE DORWARD-KING2Reason for the notificationa)Position/statusDIRECTORb)Initial Notification AmendmentINITIAL NOTIFICATION3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameKENMARE RESOURCES PLC b)LEI635400ETHWP1EKJMDO164Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type ofinstrumentORDINARY SHARES OF €0.001 EACHIdentification codeIE00BDC5DG00b)Nature of the transactionPURCHASE OF SHARESc)Price(s) and volume(s)Price(s)Volume(s)STG£4.3666400 shares d)Aggregated information— Aggregated volume— PriceORDINARY SHARES PURCHASED AT STG£4.366 EACH e)Date of the transaction2021-04-21f)Place of the transactionLONDON STOCK EXCHANGEg)Additional Information

  • Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

    LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine showed that ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with ensifentrine treatment added on to standard of care was observed in the trial. One patient death was reported in the ensifentrine treatment group. “Overall, the patients in this study recovered exceptionally well, as the mortality rate in the study was much lower than aggregate data from the hospital would have suggested over the same time period,” commented Mike Wells, MD, a pulmonologist and Principal Investigator at the University of Alabama at Birmingham Hospital. Ensifentrine is a first-in-class product candidate with both bronchodilator and anti-inflammatory activities in one compound, currently in Phase 3 clinical development for the treatment of Chronic Obstructive Pulmonary Disease (“COPD”). Clinical data from studies of ensifentrine in the treatment of other respiratory diseases have shown ensifentrine improved lung function, reduced inflammation in the lungs* and reduced symptoms of cough and sputum production. Ensifentrine has been well tolerated in clinical trials involving more than 1,300 people. Study Design The study was a double-blind, placebo controlled, unpowered pilot study designed to evaluate inhaled ensifentrine on key outcomes in patients with COVID-19 when added on to standard of care therapies, which included remdesivir and dexamethasone. The study randomized 30 patients to receive ensifentrine and 15 to placebo. Patient Population: 45 hospitalized patients with COVID-19. Single center study at University of Alabama at Birmingham.Dose/Duration: patients randomized to receive 2 mg of pMDI ensifentrine or placebo, twice-daily for up to 29 days or until discharge if this occurred before 29 days. The clinical status of all patients was evaluated daily until discharge and at Day 29 and Day 60.Primary endpoint: proportion of patients recovered (not hospitalized) from COVID-19 over 29 days.Other endpoints included: safety and tolerability, time to recovery, proportion of patients with 1- and 2-point improvement on an ordinal scale, proportion of patients progressing to mechanical ventilation, duration of hospitalization, duration and incidence of oxygen use, re-hospitalization, and mortality. Further information about this study can be found at www.clinicaltrials.gov, NCT04527471. *Franciosi LG, et al., Lancet Respir Med 2013 For further information please contact: Verona Pharma plcUS Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200Victoria Stewart, Director of Communicationsinfo@veronapharma.com Argot Partners(US Investor Enquiries)Tel: +1-212-600-1902verona@argotpartners.comKimberly Minarovich / Michael Barron Optimum Strategic Communications(International Media and European Investor Enquiries)Tel: +44 (0)203 950 9144verona@optimumcomms.comMary Clark / Eva Haas / Shabnam Bashir About Ensifentrine Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3” and “PDE4”). This dual inhibition enables it to combine both bronchodilator and anti-inflammatory effects in one compound. Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), which is beneficial in reducing mucous viscosity and improving mucociliary clearance. Ensifentrine’s mechanism of action has the potential to alleviate respiratory symptoms such as breathlessness and cough and work against inflammation associated with COPD or inflammation triggered by viruses. Ensifentrine has demonstrated significant and clinically meaningful improvements in both lung function and symptoms, including breathlessness, in Verona Pharma’s Phase 2 clinical studies in patients with moderate to severe Chronic Obstructive Pulmonary Disease (“COPD”). In addition, nebulized ensifentrine showed further improved lung function and reduced lung volumes in COPD patients taking standard short- and long-acting bronchodilator therapy, including maximum bronchodilator treatment with dual/triple therapy. Ensifentrine has been well tolerated in clinical trials involving more than 1,300 subjects to date. About Verona Pharma Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. Forward-Looking Statements This press release, operational review, outlook and financial review contain forward-looking statements. All statements contained in this press release with respect to our operational review, outlook and financial review that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the development of ensifentrine and the progress and timing of clinical trials and data, the goals and design of clinical trials, the potential for ensifentrine to be a first-in-class phosphodiesterase 3 and 4 inhibitor and to be the first therapy for the treatment of respiratory diseases to combine bronchodilator and anti-inflammatory effects in one compound, the potential of ensifentrine to alleviate respiratory symptoms such as breathlessness and cough and work against inflammation associated with COPD or inflammation triggered by viruses, and the potential applications of ensifentrine in the treatment of COPD, cystic fibrosis, asthma and other respiratory diseases. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of ensifentrine, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of ensifentrine, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ability to develop or commercialize ensifentrine; potential delays in enrolling patients, which could adversely affect our research and development efforts and the completion of our clinical trials; we may not be successful in developing ensifentrine for multiple indications; our ability to obtain approval for and commercialize ensifentrine in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel; material differences between our “top-line” data and final data; our reliance on third parties, including clinical research organizations, clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine; and lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable; changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods; and our vulnerability to natural disasters, global economic factors and other unexpected events, including health epidemics or pandemics like the novel coronavirus (COVID-19), which has and may continue to adversely impact our business. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

  • Interim report 2021, January - March

    First quarter Net sales for the first quarter reached SEK 455 m (361), corresponding to an increase of 26%. Currency translations had a negative effect of SEK 29 m on net sales Order intake was SEK 565 m (401), corresponding to an increase of 41% Operating profit reached SEK 114 m (67) equal to a 25.0% (18.5) operating margin Profit after taxes totalled SEK 94 m (48) and earnings per share was SEK 1.93 (1.01) Cash flow from operating activities amounted to SEK 132 m (55) Last twelve months Net sales for the last twelve months reached SEK 1,560 m (1,500), corresponding to a 4% increase. Currency translations had a negative effect of SEK 51 m on net sales Order intake was SEK 1,611 m (1,484), corresponding to an increase of 9% Operating profit was SEK 335 m (250), equal to a 21.4% (16.7) operating margin Profit after taxes totalled SEK 266 m (212) and earnings per share was SEK 5.70 (4.56) Cash flow from operating activities amounted to SEK 447 m (257) Comment from the CEOFull speed ahead!At the end of last year, we saw a more positive market climate and an increased demand for HMS products. The increased demand has continued in the first quarter of 2021, even stronger than expected. We released preliminary figures on order intake, sales and profitability as early as April 8, and can now confirm and elaborate on this positive situation. The quarter’s order intake was very strong and amounted to SEK 565 m, an increase of 41% compared to the same period last year. This corresponds to an organic growth in order intake of 38%. It is particularly satisfying to see that order intake from all our brands is growing by at least 35%. The significant increase in order intake is driven by a substantially stronger end market where business has returned after 18 months of lower investment climate and pandemic effects. In addition to the general market recovery, we see temporary effects as our customers rebuild inventories after a weak 2020. There is also an effect of increasing inventories to prepare for longer delivery times for electronic components, due to the semiconductor shortage situation. In total, these effects are estimated to have had a positive effect on orders of approximately SEK 60-70 m during the quarter, which we believe is non-recurring. Sales in the first quarter also increased considerably and amounted to SEK 455 m, an increase of 26% (organic growth is 19%) compared to the corresponding period last year. Despite continued currency headwinds and challenges in sourcing of components, increasing our purchasing costs, we can continue to show a positive development in our gross margin, which amounts to 64.0% (62.4%) for the quarter. The biggest effect behind the strong gross margin is the program that was implemented in 2020 with increased efficiency in operations and selective price increases. The quarter’s operating profit amounts to a record level of SEK 114 m, a significant improvement of 70% compared to the first quarter last year. The positive result is driven by sales growth in combination with good gross margins and continued low operational expenses, partly due to reduced travelling for our staff and reduced external activities due to the pandemic. Cash flow continues to be strong at SEK 132 m (55) in the quarter, which has contributed to reducing our debt. At the end of the quarter, we had a net debt in relation to EBITDA, of 0.21 (1.13). Strong recovery in our main marketsThe biggest contributing factor to the strong quarter has been a continued recovery in our main markets – largely driven by Continental Europe, but China and Japan have also continued to develop well, and on the order side, USA has also shown record levels. Machine builders and device manufacturers in all segments have shown a strong demand for our product offerings. Within Anybus, the German automotive industry, which is an important target group for Anybus sales, has accounted for a large part of the growth through its investments in conversion to electric car production. Also, in Asia growth has been driven by Anybus, largely through the robotics and wind power industry, which takes Asia to new record levels both in terms of sales and order intake. Procentec, which was acquired in the previous quarter, has continued to develop very well, with organic growth of 75% and sales of SEK 52 m, driven by a number of new key customers in Logistics. Roll-out of the HMS 2025 strategyDuring the quarter, we continued the work of implementing the HMS 2025 strategy, presented during the latter part of 2020. Among other things, we strengthened our resources within the important functions M&A and sustainability, two of the main areas in our new strategy. After setting the wheels in motion last year, we have now begun further expansion in China and investments in other interesting markets in Southeast Asia. In the near future, we will also make further investments in building our team for long-term organic growth in Industrial ICT (Information & Communication Technology), towards our goals in 2025: Revenue of more than SEK ”π” (3.14) billion, to be CO2 net positive, and to reach our high ambitions for customer and employee satisfaction. Positive outlook for 2021The recovery has been somewhat faster than we previously expected, and although the first quarter has some positive non-recurring effects, we expect to see continued strong demand in 2021. Of course, there are still uncertainties about what happens with the pandemic, but we assess the risks as lower for each month that passes with more and more people vaccinated. Despite strong demand, we are able to deliver as usual, but we see that our strong order intake in combination with increasing lead times for sourcing semiconductor components means that we can expect certain delivery time increases for customers. The price situation for semiconductors is also expected to increase in the future. As previously communicated, we see increased interest in our offering within Remote Access, which we believe will continue to have a strong market even after the pandemic. We also estimate that our operational expenses will increase during the year with new investments and gradually better conditions for travelling and customer meetings. We continue to work with a focus on long-term growth with a balanced cost level. In the long term, we continue to believe that the market for Industrial ICT (Information & Communication Technology) will be an interesting area, both in terms of organic growth and acquisitions. Halmstad April 23, 2021 Staffan Dahlström Verkställande Direktör Further information can be obtained from: Staffan Dahlström, CEO, +46 (0) 35 17 2901 Joakim Nideborn, CFO, +46 (0) 35 710 6983 This information is such that HMS Networks AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the contact persons set out above, at 08.00 CET on April 23, 2021. HMS Networks AB (publ) is a market-leading provider of solutions in industrial information and communication technology (Industrial ICT). HMS develops and manufactures products under the Anybus®, Ixxat®, Ewon® and Intesis® brands. Development takes place at the headquarter in Halmstad and also in Ravensburg, Nivelles, Igualada, Wetzlar Buchen and Delft. Local sales and support are handled by branch offices in Germany, USA, Japan, China, Singapore, Italy, France, Spain, the Netherlands, India, UK, Sweden, South Korea and UAE, as well as through a worldwide network of distributors and partners. HMS employs over 700 people and reported sales of SEK 1,467 million in 2020. HMS is listed on the NASDAQ OMX in Stockholm, category Mid Cap, Information Technology Attachment HMS Networks Q1 Report 2021

  • Invitation Ordinary General Meeting May 26th, 2021

    Naamloze Vennootschap Nijverheidsstraat 2, 2340 Beerse VAT BE0403.807.337 – RPR Turnhout INVITATION ORDINARY GENERAL MEETING Wednesday 26 May 2021 at 11h Important notification to the shareholders Due to the COVID-19 pandemic, the General Meeting will be organised via electronic communication. The shareholders can only participate via electronic communication (Zoom Video Call). Therefore the shareholders are requested to provide their email address when registering for participation.The shareholders are given the opportunity - in accordance with the modalities below - to ask questions in writing in advance as well as to give a proxy – preferably to the secretary of the General Meeting Ms Karin Leysen - in advance via the proxy form with voting instructions. Practical information regarding the electronic participation can be found on the website: www.campine.com/investors/shareholder information/general meetings. The shareholders are invited to participate in the Ordinary General Meeting, which will be held on Wednesday 26 May 2021 at 11h at Campine, Nijverheidsstraat 2, 2340 Beerse (solely via electronic communication - video call), with the following agenda and proposals: Reading and discussion about the report of the Board of Directors, the annual accounts and consolidated annual accounts of the financial year closed on 31 December 2020. Reading of and discussion about the Auditor’s Report on the above mentioned accounts. Approval of the annual accounts of the financial year closed on 31 December 2020 Resolution proposal: The Ordinary General Meeting approves the annual accounts of the financial year closed on 31 December 2020. Approval of the appropriation of the result of the financial year closed on 31 December 2020. Resolution proposal: The Ordinary General Meeting decides to appropriate the result of the financial year closed on 31 December 2020 as proposed by the Board of Directors. The Ordinary General Meeting decides to distribute a dividend of € 0.975 mio (this means € 0.65 gross per share) against presentation of coupon no 12, with payment date: 11 June 2021 (ex-date: 9 June 2021 and record date: 10 June 2021). Approval of the Remuneration Policy of the company.Resolution proposal: The Ordinary General Meeting approves the Remuneration Policy as mentioned in the annual report 2020. 6. Approval of the Remuneration Report of the financial year closed on 31 December 2020. Resolution proposal: The Ordinary General Meeting approves the Remuneration Report of the financial year closed on 31 December 2020. 7. Discharge to the Board members for the financial year closed on 31 December 2020. Resolution proposal: The Ordinary General Meeting grants discharge to the Board members for the execution of their mandate during the financial year closed on 31 December 2020. Discharge to the Auditor for the financial year closed on 31 December 2020. Resolution proposal: The Ordinary General Meeting grants discharge to the Auditor for the execution of his mandate during the financial year closed on 31 December 2020. Statutory nominations: 9a. Appointment of EY Bedrijfsrevisoren, represented by Harry Everaerts as statutory auditor of the company for a period of 3 years. Article 41 of the EU Regulation 537/2014 states that as of June 17, 2020, a public interest entity shall not grant or renew an audit engagement to a particular statutory auditor or audit firm, if, on the date of entry into force of this regulation, that statutory auditor or audit firm has provided statutory audit services to that public interest organization for a continuous period of twenty or more years. As a result, Deloitte Bedrijfsrevisoren, represented by Luc Van Coppenolle, must resign after the General Meeting in May 2021 that decides on the annual accounts for 2020, given that the indicated term expires at that time. The Board of Directors proposes to appoint EY Bedrijfsrevisoren, represented by Harry Everaerts, as Statutory Auditor for a period of 3 years.Resolution proposal: The Ordinaryl General Meeting relieves Deloitte Bedrijfsrevisoren, represented by Luc Van Coppenolle, from its mandate as statutory auditor from as of the financial year 2021, and grants Deloitte Bedrijfsrevisoren discharge from liability for the exercise of its mandate until May 26, 2021. The Ordinary General Meeting decides, on the proposal of the audit committee, to appoint EY Bedrijfsrevisoren BV, with registered office at De Kleetlaan 2, 1831 Diegem, and registered with the Crossroads Bank for Enterprises under number 0446.334.711 (RPR Brussels), represented by its permanent representative Harry Everaerts Bedrijfsrevisor BV, with registered office at Grote Heimelinkstraat 111, 9100 Sint-Niklaas, represented by its permanent representative, Mr. Harry Everaerts, as statutory auditor of the Company, with immediate effect. The mandate will end at the Ordinary General Meeting to be held in the year 2024. In accordance with article 3:77 of the Companies and Associations Code, the statutory auditor will also audit the consolidated annual accounts of the Company. The fee for the mandate as statutory auditor (both for auditing the statutory and consolidated annual accounts of the Company) amounts to EUR 47,500 per year (indexed annually, excluding VAT and other local taxes, expenses and expenses). 9b. Appointment of FLG Belgium SRL, represented by its permanent representative Ms Dina Brughmans, as independent Director for a period of 4 years. : The mandate of FLG Belgium SRL, represented by its permanent representative Ms Dina Brughmans as independent Director ends. Proposal to renew the mandate of FLG Belgium SRL, represented by its permanent representative Ms Dina Brughmans as independent Director for a period of 4 years. The Board has determined that YASS BV, represented by its permanent representative Ms Dina Brughmans, complies with all criteria required by the Companies and Associations Code and the Company Code and thus can be considered as an independent Director.Resolution proposal: The Ordinary General Meeting decides to appoint FLG Belgium SRL, represented by its permanent representative Ms Dina Brughmans, as independent Director for a period of 4 years. The mandate ends automatically, unless renewed, after the Annual Meeting held in 2025. The Directors’ remuneration amounts to € 20.500 for 2021. According to the Articles of Association the amount is automatically increased by € 250 on the first day of each new financial year. 9c. Appointment of Mr F.-W. Hempel as Director.: The mandate of Mr F.-W. Hempel ends. Proposal to renew the mandate of Mr F.-W. Hempel as Director for a period of 4 years.Resolution proposal: The Ordinary General Meeting approves the renewal of the mandate of Mr F.-W. Hempel, as Director for a period of 4 years. The mandate ends automatically, unless renewed, after the Annual Meeting held in 2025. The Directors’ remuneration amounts to € 20.500 for 2021. According to the Articles of Association the amount is automatically increased by € 250 on the first day of each new financial year. 10.Any other business Please note that you are required to comply with the following conditions and requirements: CONDITIONS OF ADMISSIONOnly the person who is an official shareholder on the Registration date (Wednesday 12 May 2021 at twenty four (24:00) hour) - either by means of a registration in the Company’s register of shares or by means of a registration on the accounts of the recognised account holders or clearing institution – are admitted to the Ordinary General Meeting, irrespective of the number of shares in his possession on the date of the Ordinary General Meeting. Furthermore, the shareholder confirms his participation to the Ordinary General Meeting ultimately on Thursday 20 May 2021 (16:00). The shareholders are requested to provide their email address when registering: The holder of registered shares: in writing to the company (see contact registered office);The holder of dematerialised shares: to Euroclear Belgium Belgium: due to Covid-19 preferably by email: ebe.issuer@euroclear.com. The recognised account holder, or the clearing institution issues the necessary certificate to the shareholder indicating the total number of dematerialised shares, respectively delivered or registered in his name in his account on the Registration date, with which the shareholder wants to participate in this General Meeting. ADD ITEMS TO THE AGENDAOne or more shareholders holding together at least 3% of the share capital may add items to the agenda of this General Meeting and submit resolution proposals relating to topics already included or to be included on the agenda. These requests must be addressed to the Company (see contact registered office) ultimately on Tuesday 4 May 2021. The shareholders who exercise this right must: prove that on the date of their request, they possess the required percentage of the share capital (by a certificate of registration of the registered shares in the Company's register of shares or by a certificate issued by a recognised account holder or clearing institute indicating that the respective number of dematerialised shares are registered in their name in an account.) and;prove that on the Registration date they are still shareholder holding together at least 3% of the share capital. When appropriate, the revised agenda and adjusted form to vote by proxy will be made public ultimately on 11 May 2021. Nevertheless, the proxies received by the Company prior to the publication of the revised agenda, remain valid for the items mentioned on the agenda. Exceptionally contradictory to the above mentioned, the proxy holder can - in compliance with article 7:130 of the Code on Companies and Associations - during this General Meeting, deviate from possible instructions of the proxy principal, for items mentioned on the agenda, for which new resolutions were submitted, if the execution of these instructions could damage the interest of the proxy principal. The proxy holder has to inform the proxy principal in this case. The proxy should mention whether the proxy holder is entitled to vote on new items put on the agenda or whether he has to abstain from them. RIGHT TO ASK QUESTIONS Pursuant to the Code on Companies and Associations and under certain conditions, the shareholders can submit questions in writing, prior this General Meeting, to the Board or the Auditor regarding their report or items mentioned on the agenda. These questions will be handled during this General Meeting if (i) the shareholder complies with the participation formalities and (ii) as far as the communication of information or facts does not prejudice Campine nv's business interests nor the confidentiality to which Campine nv, its Board of Directors or Auditor have committed themselves.These questions can be submitted in writing or per email beforehand to the Company (see contact registered office ultimately on Thursday 20 May 2021 (16:00h). VOTING BY PROXYEach shareholder who wants to be represented has to comply with the above mentioned registration and confirmation of participation procedures. Each shareholder who complies with the formalities for admission to this General Meeting provided for by the law and the Company's Articles of Association may designate one person – preferably Ms Karin Leysen, secretary of the General Meeting - to represent him at this General Meeting in accordance with the Code on Companies and Associations by means of the form to vote by proxy which can be found on the website www.campine.com/investors/shareholders information/general meetings and is available on request (see contact information registered office). Every appointment of a proxy holder has to be made in compliance with Belgian legislation, especially regarding conflict of interest and the register keeping. The notification of the appointment of a proxy holder must be received ultimately on Thursday 20 May 2021 (16:00h) in writing or by electronic means to the Company (see Contact registered office) or to Euroclear Belgium Belgium: due to Covid-19 preferably by email: ebe.issuer@euroclear.com. FORMALITIESAs of Friday 23 April 2021, the documents to be presented to this General Meeting are available on the website www.campine.com/investors/shareholder information/general meetings and financial publications) or can be consulted at the registered office and are also available – free of charge – on request via letter, fax, tel or email to the registered office attn. Karin Leysen. Contact registered officeCampine nv, Nijverheidsstraat 2, 2340 Beerse, www.campine.comAtt: Karin Leysen: karin.leysen@campine.com, tel: 014/60 15 49 Attachments decision to appoint FLG proxy invitation

  • QPR Software Interim Report January - March 2021

    QPR SOFTWARE STOCK EXCHANGE RELEASE, APRIL 23, 2021 AT 9:00 AM Profitability improved and net sales increased, driven by software sales January - March 2021 Net sales increased to EUR 2,904 thousand (January – March 2020: 2,789).Software net sales increased 6%, license and SaaS net sales grew, but maintenance net sales decreased. Consulting net sales were on the same level as in previous year.International net sales represented 50% of Group net sales (50).Operating result (EBIT) increased to EUR 286 thousand (45) and was 10% of net sales (2).Expenses were smaller than in the previous year mainly due to smaller reseller commissions. Direct sales represented a significantly larger proportion of software sales than in the previous year.Result before taxes EUR 206 thousand (36). Earnings per share EUR 0.014 (0.001). Business operations QPR Software´s mission is to make customers agile and efficient in their operations. We innovate, develop, and sell software aimed at analyzing, monitoring, and modeling operations in organizations. Furthermore, we offer customers consulting services related to our software. Outlook for 2021 (unchanged) The exceptional circumstances caused by the pandemic continue to have an impact on our business, but we are already seeing signs of normalization in software purchase decisions. Based on actual sales performance in early 2021 and current sales funnel, QPR expects net sales to grow in 2021 (2020: EUR 8,971 thousand). QPR plans to moderately increase its sales, marketing and product development costs this year. Despite the planned increase in costs, the Company estimates EBITDA and operating result to improve compared to 2020. KEY FIGURES EUR in thousands, unless otherwise indicatedJan-Mar, 2021Jan-Mar, 2020Change, %Jan-Dec, 2020 Net sales2,9042,78948,971EBITDA56639045248 % of net sales19.514.0 2.8Operating result28645530-936 % of net sales9.81.6 -10.4Result before tax20636467-952Result for the period170111,450-812 % of net sales5.90.4 -9.0 Earnings per share, EUR (basic and diluted)0.0140.0011,450-0.068Equity per share, EUR0.1760.224-210.161 Cash flow from operating activities906409122334Cash and cash equivalents85757250185Net borrowings1-343-100762Gearing, %0.0-12.3-10038.0Equity ratio, %40.951.4-2034.6Return on equity, %32.51.61,955-34.1Return on investment, %38.17.1440-28.0 REPORTING QPR Software innovates, develops, sells and delivers software and services in international markets aimed at facilitating operational development in organizations. QPR Software reports one operating segment: Operational development of organizations. In addition to this, the Company reports revenue from products and services as follows: Software licenses, Renewable software licenses, Software maintenance services, SaaS (Software-as-a-service) and Consulting. Recurring revenue reported by the Company consists of Saas net sales, Renewable software licenses and Software maintenance services. Software licenses are sold to customers for perpetual use or for an agreed, limited period. Renewable software licenses are sold to customers as a user right with an indefinite duration. These contracts are automatically renewed at the end of the agreed period, usually one year, unless the agreement is terminated within notice period. Renewable license revenue is recognized at one point in time, in the beginning of the invoicing period. Geographical areas reported are Finland, the rest of Europe (including Russia and Turkey), and the rest of the world. Net sales are reported according to the customer´s headquarter location. REVIEW BY THE CEO The year 2021 had a positive start with an increase in net sales and a significant profitability improvement, despite the continuing coronavirus pandemic. In the past year we have strengthened our process mining business by recruiting new sales and development resources. This year we will continue this development by building new sales and consulting partnerships especially in our European key markets. The new visual reporting tool in QPR ProcessAnalyzer software has helped to expand its use in customer organizations and further strengthened the competitiveness of this product. Furthermore, performance in processing large amounts of data has been significantly improved, and the software is now available localized in eight languages. Great user experience, high performance and excellent service scalability remain our priorities. To support our process modeling customers in their operations and quality systems, we will continue this year the development of a new software tool QPR BusinessPortal. With the help of this tool, our customers can communicate their processes and quality documentation to their personnel, as well as to get better visibility to their service and application portfolios. QPR BusinessPortal is now on a piloting phase and will be fully launched to the markets this year. The excellent sales development of our performance management software QPR Metrics in the Middle East market was continued in February, when QPR signed a major agreement with a large central government organization to deliver strategy management solution. The value of the deal is approximately EUR 1.2 million, and we estimate that almost EUR 1 million of the deal value will be booked into net sales over the course of 2021. Based on this deal, actual sales performance in early 2020 and current sales funnel, we expect net sales to grow in 2021. Furthermore, profitability is expected to improve, despite the planned moderate increase in sales, marketing and product development costs. Jari Jaakkola CEO NET SALES DEVELOPMENT January – March 2021 Net sales in the first quarter increased to EUR 2,904 thousand (2,789). The share of recurring revenue was 44% of net sales (47). New software license net sales amounted to EUR 734 thousand (587) and grew by 25 %, due to increase in international software sales. Renewable software license net sales decreased to EUR 443 thousand (487), which was mainly due to customer transitions to use our cloud services (SaaS). Software maintenance net sales were EUR 518 thousand (571), and decreased by 9% mainly due to decrease in international channel sales. SaaS net sales amounted to EUR 323 thousand (263). Consulting net sales remained on the same level than in the previous year and amounted to EUR 886 thousand (880). International net sales increased by 4%, as well as net sales in Finland. Of the Group net sales, 50% (50) derived from Finland, 24% (26) from the rest of Europe (including Russia and Turkey) and 26% (24) from the rest of the world. NET SALES BY PRODUCT GROUP EUR in thousandsJan-Mar, 2021Jan-Mar, 2020Change, %Jan-Dec, 2020 Software licenses734587251,344Renewable software licenses443487-9900Software maintenance services518571-92,195Cloud services323263231,081Consulting88688013,452Total2,9042,78948,971 NET SALES BY GEOGRAPHIC AREA EUR in thousandsJan-Mar, 2021Jan-Mar, 2020Change, %Jan-Dec, 2020 Finland1,4481,38944,718Europe incl. Russia and Turkey687733-62,474Rest of the world769667151,780Total2,9042,78948,971 FINANCIAL PERFORMANCE January – March 2021 The Group´s operating result (EBIT) was EUR 286 thousand (45) and represented 10% of net sales (2). The increase in operating result was mainly due to higher net sales and smaller reseller commissions than in the previous year. The share of direct sales in new software sales increased significantly from the previous year. Personnel expenses increased to EUR 1,772 thousand (1,739) and represented 78% of fixed costs. Outlays in European sales resources, general salary increases as well as higher bonus reservations in short-term incentive system increased our personnel expenses. On the other hand, expenses were lowered by temporary part-time lay-offs in January-March. The Group´s fixed costs in the reporting period were EUR 2,281 thousand (2,304). Result before taxes was EUR 206 thousand (36) and result for the period was EUR 170 thousand (11). Taxes recorded for the period were EUR 35 thousand (25) and earnings per share (basic and fully diluted) were EUR 0.014 (0.001). FINANCE AND INVESTMENTS Cash flow from operating activities was EUR 906 thousand (409). Increase in cash flow was mainly due to higher net sales and a decrease in operative working capital. Cash and cash equivalents at the end of the reporting period were EUR 857 thousand (572). Net financial expenses were EUR 80 thousand (9) and included a one-off guarantee payment related to a closed project. The payment was made in January 2021. Investments totaled EUR 184 thousand (278) and were mainly product development expenditure. The Group´s financial position is good. Cash and cash equivalents at the end of the reporting period were EUR 857 thousand (572), and in addition the Group has access to EUR 1.3 million other short-term financial instruments. At the end of the period, the Group had a short-term bank loan of EUR 700 thousand and no long-term interest-bearing bank loans. The gearing ratio was 0% (-12). At the end of the reporting period, the equity ratio was 41% (51). PRODUCT DEVELOPMENT QPR innovates and develops software products that analyze, measure and model operations in organizations. The Company develops the following software products: QPR ProcessAnalyzer, QPR EnterpriseArchitect, QPR ProcessDesigner, and QPR Metrics. In the first quarter product development expenses were EUR 486 thousand (579). Product development expenses worth EUR 174 thousand (231) were capitalized. The amortization of capitalized product development expenses was EUR 178 thousand (226). The amortization period for capitalized product development expenses is four years. PERSONNEL At the end of the reporting period, the Group employed a total of 81 persons (82). The average number of personnel during the reporting was 84 (83). The average age of employees is 42.2 (42.1) years. Women account for 22% (21) of employees and men for 78% (79). Of the total, 18% (17) work in sales and marketing, 44% (44) in consulting and customer care, 30% (32) in product development and 8% (9) in administration. For incentive purposes, the Company has a bonus program that covers all employees. Short term remuneration of the top management consists of salary, fringe benefits, and a possible annual bonus based mainly on the Group and business unit net sales performance. Furthermore, the Company has a key employee stock option plan in use. SHARES AND SHAREHOLDERS Trading of sharesJan-Mar, 2021Jan-Mar, 2020Change, %Jan-Dec, 2020 Shares traded, pcs666,969253,0971641,403,426Volume, EUR1,420,641546,9991602,825,365% of shares5.62.1 11.7Average trading price, EUR2.132.16-12.01 Shares and market capitalizationMar 31, 2021Mar 31, 2020Change, %Dec 31, 2020 Total number of shares, pcs12,444,86312,444,863-12,444,863Treasury shares, pcs457,009457,009-457,009Book counter value, EUR0.110.11-0.11Outstanding shares, pcs11,987,85411,987,854-11,987,854Number of shareholders1,2891,167101,240Closing price, EUR2.081.9382.24Market capitalization, EUR24,934,73623,136,558826,852,793Book counter value of all treasury shares, EUR50,27150,271-50,271Total purchase value of all treasury shares, EUR439,307439,307-439,307Treasury shares, % of all shares3.73.7-3.7 GOVERNANCE In March 2021, the Board of Directors gave a notice to the shareholders of QPR Software Plc that the Annual General Meeting will be held on Thursday March 25, 2021. The Board of Directors of the Company resolved on extraordinary measures pursuant to the temporary legislation approved by the Finnish Parliament. In order to prevent the spread of the Covid-19 pandemic, the Annual General Meeting was held without shareholders’ presence at the Meeting venue. Participation and exercise of shareholder rights in the Meeting was possible only by way of proxy representation, by submitting counterproposals and asking questions in advance. The Annual General Meeting approved the Board's proposal that no dividend be paid for the financial year 2020. The Annual General Meeting made an advisory decision on the Remuneration Report and decided to approve the presented Remuneration Report. The Annual General Meeting resolved that the number of Board Members is four (4) and elected Pertti Ervi, Matti Heikkonen, Antti Koskela and Jukka Tapaninen members of the Company´s Board of Directors. The term of office of the members of the Board of Directors expires at the end of the next Annual General Meeting. At its organizing meeting, the Board of Directors elected Pertti Ervi as its Chairman. The Annual General Meeting elected Authorized Public Accountants KPMG Oy Ab as QPR Software´s auditor with Miika Karkulahti, Authorized Public Accountant, acting as principal auditor. The term of office of the auditor expires at the end of the next Annual General Meeting. The Annual General Meeting decided to authorize the Board of Directors to decide on conveyance of the own shares held by the Company (share issue) either in one or in several occasions. The share issue can be carried out as a share issue against payment or without consideration on terms to be determined by the Board of Directors. All authorizations of the Board and other decisions made by the previous Annual General Meeting are available in their entirety in the stock exchange release published by the Company on March 25, 2021. The release can be found in Investors section of the Company's website, https://www.qpr.com/investors/stock-exchange-and-press-releases. EVENTS AFTER THE REVIEW PERIOD The Company has no significant events after the review period to report. SHORT-TERM RISKS AND UNCERTAINTIES Internal control and risk management at QPR Software aims to ensure that the Company operates efficiently and effectively, distributes reliable information, complies with regulations and operational principles, reaches its strategic goals, reacts to changes in the market and operational environment, and ensures the continuity of its business. QPR has identified the following three groups of risks related to its operations: risks related to business operations (country, customer, personnel, legal), risks related to information and products (QPR products, IPR, data security) and risks related to financing (foreign currency, short-term cash flow). The Company has an insurance policy covering property, operational and liability risks. Financial risks include reasonable credit risk concerning individual business partners, which is characteristic of any international business. QPR seeks to limit this credit risk by continuously monitoring standard payment terms, receivables and credit limits. Approximately 63% of the Group’s trade receivables were in euro at the end of the quarter (52). At the end of the quarter, the Company had not hedged its non-euro trade receivables. Risks and risk management practices related to the Company’s business are further described in the Annual Report 2020, pages 22-24 (https://www.qpr.com/investors/financial-information/annual-reports) FINANCIAL INFORMATIONIn 2021, QPR Software Plc will publish its financial information, in Finnish and English, as follows: Half-year Financial Report 1-6/2021: Wednesday, August 4, 2021Interim Report 1-9/2021: Friday, October 22, 2021 QPR SOFTWARE PLC BOARD OF DIRECTORS Further information: Jari Jaakkola, CEO, Tel. +358 (0) 40 5026 397 DISTRIBUTION:NASDAQ OMX Helsinki Ltd Main Media Neither this press release nor any copy of it may be taken, transmitted or distributed, directly or indirectly, in or into the United States of America or its territories or possessions. FINANCIAL STATEMENTS CONSOLIDATED COMPREHENSIVE INCOME STATEMENT EUR in thousands, unless otherwise indicatedJan-Mar, 2021Jan-Mar, 2020Change, %Jan-Dec, 2020 Net sales2,9042,78948,971Other operating income -- 100 Materials and services337440-231,422Employee benefit expenses1,7721,73926,649Other operating expenses2282204753EBITDA56639045248 Depreciation and amortization280345-191,183Operating result28645530-936 Financial income and expenses-80-9786-16Result before tax20636467-952 Income taxes-35-2539140Result for the period170111,450-812 Earnings per share, EUR (basic and diluted)0.0140.0011,450-0.068 Consolidated statement of comprehensive income: Result for the period170111,450-812Other items in comprehensive income that may be reclassified subsequently to profit or loss: Exchange differences on translating foreign operations1139-3Total comprehensive income172121,344-814 CONDENSED CONSOLIDATED BALANCE SHEET EUR in thousandsMar 31, 2021Mar 31, 2020Change, %Dec 31, 2020 Assets Non-current assets: Intangible assets2,0332,02212,054 Goodwill5135130513 Tangible assets16410064176 Right-of-use assets121226-47211 Other non-current assets27762347277Total non-current assets3,1082,92363,231 Current assets: Trade and other receivables2,6492,698-22,901 Cash and cash equivalents85757250185Total current assets3,5063,27073,086 Total assets6,6146,19376,317 Equity and liabilities Equity: Share capital1,3591,35901,359 Other funds2121021 Treasury shares-439-4390-439 Translation differences-67-653-69 Invested non-restricted equity fund5505 Retained earnings1,3111,907-311,126Equity attributable to shareholders of the parent company2,1902,788-212,004 Current liabilities: Interest-bearing liabilities700- 700 Interest-bearing lease liabilities158229-31247 Advances received1,26376665527 Accrued expenses and prepaid income1,6931,853-92,305 Trade and other payables61055610533Total current liabilities4,4243,405304,313 Total liabilities4,4243,405304,313 Total equity and liabilities6,6146,19376,317 CONSOLIDATED CONDENCED CASH FLOW STATEMENT EUR in thousandsJan-Mar, 2021Jan-Mar, 2020Change, %Jan-Dec, 2020 Cash flow from operating activities: Result for the period170111,450-812 Adjustments to the result203389-481,135 Working capital changes678232,84545 Interest and other financial expenses paid-142-22-555-40 Interest and other financial income received213-8827 Income taxes paid-5-5-1-21Net cash from operating activities906409122334 Cash flow from investing activities: Purchases of tangible and intangible assets-157-301-48-1,098Net cash used in investing activities-157-301-48-1,098 Cash flow from financing activities: Proceeds from short term borrowings700- 700 Repayments of short term borrowings-700-50040-500 Payment of lease liabilities-89-7618-261Net cash used in financing activities-89-576-84-61 Net change in cash and cash equivalents 660-468241-825Cash and cash equivalents at the beginning of the period1851,035-821,035Effects of exchange rate changes on cash and cash equivalents125152-25Cash and cash equivalents at the end of the period85757250185 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY EUR in thousandsShare capitalOther fundsTranslation differencesTreasury sharesInvested non- restricted equity fundRetained earningsTotalEquity Jan 1, 20201,35921-66-43951,8822,762Stock option scheme 1414Comprehensive income 1 1112Equity March 31, 20201,35921-65-43951,9072,788Stock option scheme 4242Comprehensive income -4 -823-826Equity Dec 31, 20201,35921-69-43951,1272,004Stock option scheme 1414Comprehensive income 1 170172Equity March 31, 20211,35921-68-43951,3112,190 NOTES TO INTERIM FINANCIAL STATEMENTS ACCOUNTING PRINCIPLES This report complies with requirements of IAS 34 ”Interim Financial Reporting”. Starting from the beginning of 2021, the Group has applied certain new or revised IFRS standards and IFRIC interpretations, as described in the Consolidated Financial Statements 2020. The implementation of these new and revised requirements has not impacted the reported figures. For all other parts, the accounting principles and methods are the same as they were in the 2020 financial statements. When preparing the consolidated financial statements, management is required to make estimates and assumptions regarding the future and to consider the appropriate application of accounting principles, which means that actual results may differ from those estimated. All amounts presented in this report are consolidated figures, unless otherwise noted. The amounts presented in the report are rounded, so the sum of individual figures may differ from the sum reported. This report is unaudited. INTANGIBLE AND TANGIBLE ASSETS EUR in thousandsJan-Mar, 2021Jan-Mar, 2020Jan-Dec, 2020 Increase in intangible assets: Acquisition cost Jan 111,98711,15911,159 Increase174228828 Increase in tangible assets: Acquisition cost Jan 12,6222,4872,487 Increase1050135 CHANGE IN INTEREST-BEARING LIABILITIES EUR in thousandsJan-Mar, 2021Jan-Mar, 2020Jan-Dec, 2020 Interest-bearing liabilities Jan 1947784784Proceeds from short term borrowings70021947Repayments789576784Interest-bearing liabilities Sep 30858229947 PLEDGES AND COMMITMENTS EUR in thousandsJan-Mar, 2021Jan-Mar, 2020Dec 31, 2020Change, % Business mortgages (held by the Company)2,3862,3822,3870 Minimum lease payments based on lease agreements: Maturing in less than one year7870 Maturing in 1-5 years5147-25Total122214-10 Total pledges and commitments2,3982,4042,4010 CONSOLIDATED INCOME STATEMENT BY QUARTER EUR in thousandsQ1 2021Q4 2020Q3 2020Q2 2020Q1 2020 Net sales2,9042,3411,8012,0412,789Other operating income--7525- Materials and services337443279260440Employee benefit expenses1,7721,6791,4741,7571,739Other operating expenses228193232109220EBITDA56627-109-60390 Depreciation and amortization280211304324345Operating result286-184-413-38445 Financial income and expenses-80-8-66-9Result before tax206-191-419-37836 Income taxes-35347457-25Result for the period170-157-345-32111 GROUP KEY FIGURES EUR in thousands, unless otherwise indicatedJan-Mar or Mar 31, 2021Jan-Mar or Mar 31, 2020Jan-Dec or Dec 31, 2020 Net sales2,9042,7898,971Net sales growth, %4.11.5-5.7EBITDA566390248 % of net sales19.514.02.8Operating result28645-936 % of net sales9.81.6-10.4Result before tax20636-952 % of net sales7.11.3-10.6Result for the period17011-812 % of net sales5.90.4-9.0 Return on equity (per annum), %32.51.6-34.1Return on investment (per annum), %38.17.1-28.0Cash and cash equivalents857572185Net borrowings1-343762Equity2,1902,7882,004Gearing, %0.0-12.338.0Equity ratio, %40.951.434.6Total balance sheet6,6146,1936,317 Investments in non-current assets1572781,210 % of net sales5.410.013.5Product development expenses4865792,050 % of net sales16.720.822.9 Average number of personnel848386Personnel at the beginning of period888383Personnel at the end of period818188 Earnings per share, EUR (basic and diluted)0.0140.001-0.068Equity per share, EUR0.1760.2240.161

  • 11 Hollyoaks spoilers for next week

    What's next in the village?

  • TP Vision: Philips Soundbar With Subwoofer Delivers Powerfully Cinematic Sound

    Now available in the UAE, the Philips TAB8805 3.1 channel Soundbar with subwoofer lets you make more of movie night. The immersive 3D audio of Dolby Atmos puts you right in the middle of the scene, and Play-Fi compatibility makes it easy to create a true surround-sound setup.

  • Bones of Black children killed in police bombing used in Ivy League anthropology course

    Bones of Black children killed in police bombing used in Ivy League anthropology course. Remains of those killed in 1985 Move bombing in Philadelphia serve as ‘case study’ in Princeton-backed course

  • Poundless Program Reviews: Legit Weight Loss Results System?

    The Poundless Program by Adam Diehl is a system setup to yield real weight loss results, centered upon a breakthrough discovery of a completely natural and scientifically proven 3-step trick towards burning fat with safe eating plans and smoothie recipes, but are there negative customer complaints or is it worth the money? Poundless Program Reviews Poundless Program Reviews Chicago, IL, April 23, 2021 (GLOBE NEWSWIRE) -- The Poundless Program is a weight loss program that is made to help guide you into losing up to 57 pounds of fat. By following the Poundless Program weight loss strategies in the eBooks and PDFs, you can purportedly lose a significant amount of weight in a short period of time. Does The Poundless Program really work? Can you really lose 57 pounds by following the program? Find out everything you need to know about this weight loss system and how it works today in our review. What is The Poundless Program? The Poundless Program is a weight loss program sold exclusively online through PoundlessProgram.com. The program consists of eBooks, digital guides, and online manuals. You buy the program online, then receive instant access. You can start implementing the lessons immediately. According to the official website, one man lost 57 pounds of excess body fat while following The Poundless Program. That man needed to lose weight to give his daughter a kidney that would save her life. He lost a significant amount of weight in a short period of time, ultimately saving his daughter’s life. Obviously, all weight loss programs make similar claims. All weight loss programs claim to help you lose weight and burn fat, for example. What makes The Poundless Program different from other weight loss systems? Keep reading to find out. How Does The Poundless Program Work? The Poundless Program is based on the idea that small strategies can change the way your body approaches appetite, weight loss, and dieting. By making small changes to your lifestyle today, you can snowball those changes into significant improvements. Inside The Poundless Program, you’ll get basic advice about the right foods to eat for losing weight, including foods to add to your diet and foods to avoid. The program also includes a book of five minute workouts you can perform at home. You don’t need to spend hours at the gym to lose weight. Sometimes, a five minute daily workout is all you need. Other topics covered in The Poundless Program include smoothie recipes, the value of healthy foods, and naturally lowering your body’s setpoint weight to ensure effective weight loss results. The program also emphasizes the importance of detoxifying your body. Some of the smoothie recipes in The Poundless Program claim to specifically target heavy metals, toxins, and inflammation in your body, for example. By detoxifying your body, you can cleanse it of harmful compounds. Three Myths About Weight Loss Adam, the person who created The Poundless Program, claims big pharmaceutical companies, supplement companies, and food companies have teamed up to suppress the real cures for weight loss. These groups make billions off of fat people, and they want to keep people overweight. With that in mind, Adam claims these groups promote certain myths about weight loss: Myth #1: Dieting Will Help You Lose Weight: Adam claims it’s a myth that dieting will help you lose weight. He claims restricting calories and following a careful diet are “worthless” because they fail “again and again.” He claims starvation dieting is worth for your health than being overweight, and that it actually contributes to weight gain in the long run by wrecking your metabolism. For all of these reasons, Adam recommends that you don’t diet, count calories, or restrict what you eat to lose weight. Myth #2: Calories Are All the Same: Some people claim a calorie is a calorie. 10 calories of chocolate is the same as 10 calories of salmon. However, Adam says that’s not true because foods have different macronutrient levels. Some foods are rich with protein, vitamins, and minerals, for example, while others are rich with processed sugars and fats. Although the number of calories might be equal, the nutritional value of foods is not equal. Myth #3: You Need to Exercise “Like a Crazy Person” to Lose Weight: Adam claims you don’t need to exercise much to lose weight. In fact, he recommends against exercising “like a crazy person” because it puts too much stress on your metabolism and body. Your body produces cortisol when you work out, and cortisol can force you to gain weight. Countless studies show that exercise is good for weight loss, but Adam advises against it. Overall, Adam claims that dieting and exercising will not lead to significant weight loss results: “…no diet, exercise programs or restrictions will help you achieve your weight loss goals…these are not the true cause of your weight loss resistance.” Instead, Adam claims The Poundless Program will target the root cause of your weight loss issues without requiring you to diet, exercise, or exert much effort. The Story Behind The Poundless Program The Poundless Program was created by a 49-year old man named Adam Diehl. Adam lives near Greensboro, North Carolina with his wife and two daughters. Adam describes himself as “just your average Joe.” He works as a search and rescue team crew leader. He claims he was on the ground during Hurricane Harvey in 2017 and Hurricane Dorian in 2019. On the official program website, Adam mentions that he has “dedicated [his] life to helping others,” which is why he is motivated to share The Poundless Program with the world. Like many men, Adam gained weight as he got older. He was no longer the slim, skinny person he was in high school. He had gained a significant amount of weight over the years. Adam didn’t see his weight gain as a big deal until he had a “silent heart attack.” Adam was 75 pounds overweight, clinically obese, and out of shape. His doctor ordered an EKG. Based on the results of the EKG, Adam’s doctor warned him he had “one foot in the grave.” His doctor told him to lose weight or die. After the diagnosis, Adam tried weight loss routines, trendy diets like the Atkin’s diet and paleo diet, and exercise systems. Nothing worked. Adam claims he struggled to lose weight and keep it off. Things changed when Adam’s daughter was diagnosed with kidney disease. Adam’s daughter needed a kidney transplant. After a multi-year battle with kidney failure, doctors told Adam that his daughter would die without receiving a kidney. Adam wanted to give his daughter his kidney, but he was too overweight for the surgery. Adam started researching natural cures for weight loss. He needed a way to lose weight quickly and easily. That’s when Adam’s cousin Nicholas came to visit from Italy. Adam describes Nicholas as “some kind of Roman god” because of his impeccable body. Adam asked Nicholas how he did it, and Nicholas revealed his secrets. Nicholas told Adam that big pharmaceutical companies and big food manufacturers have teamed up to keep Americans fat. He claims it’s impossible to diet and exercise your way to weight loss. Instead, you just need to eat specific foods. To make a long story short, Adam claims to have lost 57 pounds of weight with minimal effort using The Poundless Program. Three years later, his daughter is happy, healthy, and successful. Adam lost weight and saved his daughter’s life thanks to The Poundless Program. Creating a Setpoint to Lose Weight Adam claims one of his best tricks for losing weight is to create a setpoint. A setpoint is your target weight. By setting the target weight in your mind, you subconsciously force your body to reach that target weight. Here’s how Adam explains the unique concept: “…it’s all down to this hidden process that is plotting against you every day making your body hold on to excess pounds…and it’s known by the name of “YOUR SETPOINT”. In short, your setpoint is the weight your body wants to be at and works to maintain by regulating your hormones that control your metabolism and hunger levels…” If you don’t create a setpoint in your brain, then your body doesn’t know how much weight to lose. Adam claims it’s “like a thermostat.” All you need to do is think about how much weight you want to lose, and your body will subconsciously create hormones to reach that target weight: “Your brain receives information through hormone signals from your body fat, muscles, pancreas liver and sensory organs at all times…And controls your appetite, digestion, energy balance and metabolism...which automatically maintain body fat at a specific level, otherwise known as your setpoint.” Creating a setpoint isn’t as easy as thinking about it. Your body naturally raises or lowers your setpoint based on your diet, exercise habits, and body composition. However, Adam claims you can naturally lower your setpoint to solve your weight loss problems. How to Naturally Lower your Setpoint to Lose Weight Adam believes lowering your setpoint can force your body to lose weight. When you lower your setpoint, you tell your body that you want to lose weight. Your body produces hormones to reach that target weight. It controls your appetite, influences your metabolism, and makes other changes to ensure you reach your setpoint and your target weight. In The Poundless Program, Adam teaches you natural ways to lower your setpoint. You can discover exercises, therapies, movements, and tricks to naturally lower your body’s setpoint. These strategies force your body into alignment, ensuring all your body systems reach towards a common goal. By eating the right foods, performing the right exercises, and making other basic changes to your life, you can purportedly lower your setpoint naturally, making it easy to lose weight. Benefits of Lowering your Setpoint Adam claims that lowering your setpoint will lead to significant weight loss and health benefits. By following The Poundless Program, you can naturally lower your setpoint and achieve significant benefits. Here are some of the benefits of lowering your setpoint, according to The Poundless Program’s sales page: Reverse brain inflammationRegenerate cells throughout your bodyRebalance the metabolic hormones that wreak havoc in your body and digestive bacteriaRemove the blockages forcing your body to cling to every ounce of fat no matter how little you eat or how much you exerciseHow to force your body to work like the body of a skinny person, turning your metabolism into a fat burning furnaceHow to get rid of unwanted pounds and keep them off for good How Much Weight Can You Lose with The Poundless Program? Adam claims he lost a significant amount of weight with The Poundless Program. Because of his success with the program, he wanted to share it with the world. The first day he started the program, Adam claims he lost 2 pounds. Over the next few days, Adam continued to lose weight. After one week of following The Poundless Program, Adam claims he lost 12 pounds “without a single minute of exercise and with just a few incredibly simple ingredient replacements.” Within three weeks of starting The Poundless Program, Adam had lost 37 pounds. He also had lower blood pressure and better cholesterol. Eventually, Adam lost 63 pounds by following The Poundless Program. He claims he also became “physically healthier than 95% of the population” after following the program. Despite being on medication for blood pressure and cholesterol, Adam claims he threw these medications in the garbage because he no longer needed them – all because he followed The Poundless Program. Adam also claims he ran a clinical trial with The Poundless Program where the average person lost 37 pounds. Some people lost more, and some people lost less, but the average weight loss was 37 pounds. Based on the official Poundless Program website, you can expect to lose an average of 37 pounds while following The Poundless Program, with some people (like Adam) losing 37 pounds in just three weeks. What Will You Learn in The Poundless Program? The Poundless Program features everything you need to follow the program, lose a significant amount of weight, and get the best body possible. Some of the topics covered in the program include: A comprehensive and easy-to-follow list of surprising foods to add to your diet toady to lose weight and revitalize your healthDelicious, detoxifying, easy-to-make smoothie recipes to enhance usefulness, eliminate destructive toxins, and get rid of heavy metals and free radicals in your bodyA 21-day step-by-step action plan for jumpstarting your metabolism and helping you lose weightEverything you need to know to lose weight quickly, easily, and efficientlyHow to reset your body and increase your metabolism while restoring your hormones, healing your gut, and getting rid of inflammation Overall, Adam claims his program will teach you how to become the healthiest, most energetic, and absolute best version of yourself. It’s all delivered in a no-nonsense, easy-to-understand way. Scientific Evidence for The Poundless Program Adam does not claim to be a doctor, nor does he claim to have any type of nutritional certifications, dietitian qualifications, or other experience. He’s a normal search and rescue guy from North Carolina who lost a significant amount of weight with simple changes. Adam does, however, claim to have tested The Poundless Program on people before selling it to the world. In that test, Adam claims the average person lost 37 pounds, which would make The Poundless Program one of the most successful weight loss programs in human history. Here’s how Adam describes that remarkable trial: “Within just a few weeks ALL of the people in “my little boot camp” – people who were resistant to weight loss and thought it was impossible to lose weight and keep it off no matter what they tried reported the same thing: A dramatic reduction in body fat…The average weight loss was about 37 pounds…” Adam claims the people in his trial group also experienced significant health benefits from his program, including increases in energy, reductions in cravings, and improvements in mood, sleep, and sex drive, among other measurements. Unfortunately, Adam does not provide further details about this test, like how many people were involved, what types of conditions the people followed, or how long the study lasted. He has not published his research in a peer-reviewed journal, nor has he published the study anywhere online. The Poundless Program is relatively new, although Adam claims it has helped “more than 37,311” normal people lose a significant amount of weight. That might make The Poundless Program one of the bestselling weight loss guides of all time in recent memory, but that is quite impressive number already. The Poundless Program emphasizes the role hormones play in weight loss. Adam cites this 2007 study, for example, showing the role leptin and ghrelin play in regulating food intake and body weight. Leptin and ghrelin are two hormones crucial for appetite, weight loss, energy, and body composition. When leptin and ghrelin levels are imbalanced, you struggle to lose weight. Adam also emphasizes the role that stress plays in weight gain. When your body is stressed, it creates cortisol. Too much cortisol can lead to weight gain. Adam cites this 2001 study, for example, that showed stress-induced cortisol was linked with eating behavior. In that study, researchers exposed women to a stressful situation, then tracked their eating habits. Women ate significantly more food after the stress tests – particularly sweet foods. Overall, The Poundless Program features information similar you can find on any free weight loss blog online. The program has not been reviewed or approved by a medical doctor, a dietitian, or a certified nutritionist, and there’s limited evidence you can lose an average of 37 pounds of weight by following The Poundless Program as advertised on the official sales page. What’s Included with The Poundless Program? The Poundless Program comes with everything you need to follow the program. Here’s what you get with each purchase: The Poundless Program Main Manual: This manual teaches you how to lose weight, naturally lower your setpoint, and create life-changing weight loss results. You’ll discover the core tenets of The Poundless Program and how it works, including the foods you should eat, the times of day you should eat, and the basic exercises to perform. 5 Minute Workouts: The Poundless Program is based on the idea that you can lose weight without dieting or exercising. However, all purchases come with an eBook called 5 Minute Workouts. This eBook teaches you how to perform simple workouts at home with no equipment to maximize weight loss results. Meal Planning Books: The Poundless Program features two meal planning books. Each book has recipes, meal planning tips, shopping lists, and other information about the foods you should be eating. Weight Loss Journal: Adam is a big believer in writing your way to weight loss success. Your purchase comes with a printable weight loss journal that lets you track your success with The Poundless Program. The Poundless Program Pricing The Poundless Program is priced at $39.69. The Poundless Program is a completely digital purchase. You receive instant access to all of the following immediately after your purchase is confirmed. Note: To drop the price to $22, hover your mouse over the ‘escape’ or ‘back’ button on the final sales page. You will receive a special offer dropping the price to $22. The Poundless Program Refund Policy The Poundless Program is backed by a 60 day refund policy. You can request a complete refund on your purchase within 60 days of your original purchase date. If you did not lose 37 pounds within the first few weeks of The Poundless Program, or if you’re unhappy with your weight loss results for any reason, then you can request a complete refund on the program with no questions asked. Who Created The Poundless Program? The Poundless Program was created by a company that provides limited information about itself online. Adam Diehl is a pen name, and Adam does not really exist. You can contact the makers of The Poundless Program via the following: Email: adam@poundlessprogram.com Final Word The Poundless Program is a weight loss program sold online through PoundlessProgram.com. The program was created by a man named Adam Diehl who shares the personal success story to have lost 37 pounds in 3 weeks while following the program, ultimately losing 57 pounds of fat in a short period of time. Adam also claims to have tested his program on a control group, and that control group had average weight loss of 37 pounds too. Obviously, by now, you should be skeptical any time someone promises easy, effective, painless weight loss online as it is just one of the most tried expressions in the multi-trillion dollar health and wellness personal care industry annually. Losing weight requires changes to your diet and exercise habits, but supplements and systems like The Poundless Program can be there as a guiding backbone to stay on track and do the right activities day in and day out. One might grip at the fact that there’s no direct evidence that Adam Diehl has any unique weight loss certifications or medical expertise, or there’s no proof anyone has lost weight while following The Poundless Program, but it is hard to ignore the growing demand for well-thought out thoroughly mapped health protocol guides to follow daily that is known as a quick, simple and life changing plan. To learn more about The Poundless Program and how it works, visit online today at PoundlessProgram.com, where all purchases are backed by a 60 day refund policy. Official Website: https://www.poundlessprogram.com/index-main.html Contact Details: The Poundless Program Email: adam@poundlessprogram.com About MarketingByKevin.com This product review is published by Marketing By Kevin. Marketing By Kevin reviews are researched and formulated by a group of experienced natural health advocates with years of dedication and determination to finding the highest quality health products and wellness programs available. It should be noted that any purchase derived from this resource is done at your own peril. It is recommended to consult with a qualified professional healthcare practitioner before making an order today if there are any additional questions or concerns. Any order finalized from this release’s links are subject to the entire terms and conditions of the official website’s offer. The researched information above does not take any direct or indirect responsibility for its accuracy. Affiliate Disclosure: The links contained in this product review may result in a small commission to Marketing By Kevin if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products. Disclaimer: Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. Product support: adam@poundlessprogram.com Media Contact: info@marketingbykevin.com Attachment Poundless Program Reviews CONTACT: Kevin Mahoney 708-247-1324 info@marketingbykevin.com